Publicaciones en las que colabora con Julián de la Torre Cisneros (19)

2023

  1. Role of IP-10 to Predict Clinical Progression and Response to IL-6 Blockade With Sarilumab in Early COVID-19 Pneumonia. A Subanalysis of the SARICOR Clinical Trial

    Open Forum Infectious Diseases, Vol. 10, Núm. 4

2022

  1. Early Use of Sarilumab in Patients Hospitalized with COVID-19 Pneumonia and Features of Systemic Inflammation: The SARICOR Randomized Clinical Trial

    Antimicrobial Agents and Chemotherapy, Vol. 66, Núm. 2

  2. Impact of ceftazidime/avibactam versus best available therapy on mortality from infections caused by carbapenemase-producing Enterobacterales (CAVICOR study)

    The Journal of antimicrobial chemotherapy, Vol. 77, Núm. 5, pp. 1452-1460

2020

  1. Efficacy and safety of early treatment with sarilumab in hospitalised adults with COVID-19 presenting cytokine release syndrome (SARICOR STUDY): Protocol of a phase II, open-label, randomised, multicentre, controlled clinical trial

    BMJ Open, Vol. 10, Núm. 11

2013

  1. Baseline risk factors for relapse in HIV/HCV co-infected patients treated with PEG-IFN/RBV

    Infection, Vol. 41, Núm. 1, pp. 21-26

  2. Incidence of Liver Damage of Uncertain Origin in HIV Patients Not Co-Infected with HCV/HBV

    PLoS ONE, Vol. 8, Núm. 7

2012

  1. Association between the IL28B genotype and hepatitis C viral kinetics in the early days of treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected patients with genotype 1 or 4

    Journal of Antimicrobial Chemotherapy, Vol. 67, Núm. 1, pp. 202-205

  2. LDLr genotype modifies the impact of IL28B on HCV viral kinetics after the first weeks of treatment with PEG-IFN/RBV in HIV/HCV patients

    AIDS, Vol. 26, Núm. 8, pp. 1009-1015

2011

  1. Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients

    Journal of Antimicrobial Chemotherapy, Vol. 66, Núm. 11, pp. 2605-2614

  2. Twelve week post-treatment follow-up predicts sustained virological response to pegylated interferon and ribavirin therapy in HIV/hepatitis C virus co-infected patients

    Journal of Antimicrobial Chemotherapy, Vol. 66, Núm. 6, pp. 1351-1353

2010

  1. Changes in liver stiffness in patients with chronic hepatitis C with and without HIV co-infection treated with pegylated interferon plus ribavirin

    Journal of Antimicrobial Chemotherapy, Vol. 65, Núm. 10, pp. 2204-2211

  2. Prevalence and risk factors for abnormal liver stiffness in HIV-infected patients without viral hepatitis coinfection: Role of didanosine

    Antiviral Therapy, Vol. 15, Núm. 5, pp. 753-763

  3. Usar rifampicina más pirazinamida en profilaxis antituberculosa no incrementa el riesgo de hepatotoxicidad grave en pacientes infectados por virus de la inmunodeficiencia humana: metaanálisis de ensayos clínicos aleatorizados y controlados

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 28, Núm. 4, pp. 239-244

2009

  1. Etiology of spontaneous pneumothorax in 105 HIV-infected patients without highly active antiretroviral therapy

    European Journal of Radiology, Vol. 71, Núm. 2, pp. 264-268

  2. Factores de riesgo cardiovascular dependientes del tratamiento antirretroviral

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 27, Núm. SUPPL. 1, pp. 24-32

2008

  1. Darunavir en la coinfección por VIH/VHB y/o VHC

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 26, Núm. SUPPL. 10, pp. 37-42

  2. Safety of atazanavir in patients with HIV and hepatitis B and/or C virus coinfection

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 26, Núm. SUPPL. 17, pp. 45-48

  3. Successful long-term treatment with linezolid for disseminated infection with multiresistant Nocardia farcinica

    Infection

2007

  1. Variabilidad en la valoración del riesgo coronario en pacientes infectados por el virus de la inmunodeficiencia humana

    Medicina Clinica, Vol. 129, Núm. 14, pp. 521-524